These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17250669)

  • 1. Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660).
    Lanktree M; Cao H; Rabkin SW; Hanna A; Hegele RA
    Clin Genet; 2007 Feb; 71(2):183-6. PubMed ID: 17250669
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
    Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The retinol acid receptor B gene is hypermethylated in patients with familial partial lipodystrophy.
    Cortese R; Eckhardt F; Volleth M; Wehnert M; Koelsch U; Wieacker P; Brune T
    J Mol Endocrinol; 2007 Jun; 38(6):663-71. PubMed ID: 17556535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial partial lipodystrophy due to the LMNA R482W mutation with multinodular goitre, extrapyramidal syndrome and primary hyperaldosteronism.
    Vantyghem MC; Faivre-Defrance F; Marcelli-Tourvieille S; Fermon C; Evrard A; Bourdelle-Hego MF; Vigouroux C; Defebvre L; Delemer B; Wemeau JL
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):247-9. PubMed ID: 17524034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
    Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
    J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
    Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological and molecular features of lipomatous and nonlipomatous adipose tissue in familial partial lipodystrophy caused by LMNA mutations.
    Araújo-Vilar D; Victoria B; González-Méndez B; Barreiro F; Fernández-Rodríguez B; Cereijo R; Gallego-Escuredo JM; Villarroya F; Pañeda-Menéndez A
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):816-24. PubMed ID: 21883346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series.
    Luedtke A; Boschmann M; Colpe C; Engeli S; Adams F; Birkenfeld AL; Haufe S; Rahn G; Luft FC; Schmidt HH; Jordan J
    Horm Metab Res; 2012 Apr; 44(4):306-11. PubMed ID: 22274718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A.
    Tu Y; Sánchez-Iglesias S; Araújo-Vilar D; Fong LG; Young SG
    Nucleus; 2016 Sep; 7(5):512-521. PubMed ID: 27841971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of Fragile X-related protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene expression program in preadipocytes.
    Oldenburg AR; Delbarre E; Thiede B; Vigouroux C; Collas P
    Hum Mol Genet; 2014 Mar; 23(5):1151-62. PubMed ID: 24108105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
    Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
    Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy.
    Vadrot N; Duband-Goulet I; Cabet E; Attanda W; Barateau A; Vicart P; Gerbal F; Briand N; Vigouroux C; Oldenburg AR; Lund EG; Collas P; Buendia B
    Hum Mol Genet; 2015 Apr; 24(7):2096-109. PubMed ID: 25524705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial partial lipodystrophy presenting as metabolic syndrome.
    Chan D; McIntyre AD; Hegele RA; Don-Wauchope AC
    J Clin Lipidol; 2016; 10(6):1488-1491. PubMed ID: 27919367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of an integration-free induced pluripotent stem cell line (PUMCHi001-A) from a patient with familial partial lipodystrophy type 2 (FPLD2) carrying a heterozygous p.R349W (c.1045C > T) mutation in the LMNA gene.
    Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
    Stem Cell Res; 2020 Jan; 42():101651. PubMed ID: 31794942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence.
    Caron M; Auclair M; Donadille B; Béréziat V; Guerci B; Laville M; Narbonne H; Bodemer C; Lascols O; Capeau J; Vigouroux C
    Cell Death Differ; 2007 Oct; 14(10):1759-67. PubMed ID: 17612587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: An Atypical Form of Familial Partial Lipodystrophy Type 2 Due to Mutation in the Rod Domain of Lamin A/C.
    Cecchetti C; D'Apice MR; Morini E; Novelli G; Pizzi C; Pagotto U; Gambineri A
    Front Endocrinol (Lausanne); 2021; 12():675096. PubMed ID: 33953703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
    Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
    J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of an isogenic gene-corrected iPSC line (PUMCHi001-A-1) from a familial partial lipodystrophy type 2 (FPLD2) patient with a heterozygous R349W mutation in the LMNA gene.
    Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
    Stem Cell Res; 2020 Apr; 44():101753. PubMed ID: 32213461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
    Friesen M; Cowan CA
    Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.